Clover Biopharma announced plans to build a biologic drug manufacturing facility in Changxing, Zhejiang Province.
January 25, 2018 -- Chengdu’s Clover Biopharma announced plans to build a biologic drug manufacturing facility in Changxing, Zhejiang Province. The facility, which will have two 2000-L bioreactors, will be built around GE Healthcare’s FlexFactory single-use technology. Clover will use the plant for its biological fusion protein products, including both innovative drugs and biosimilars. Last month, Clover received CFDA permission to begin China trials of its Enbrel biosimilar for rheumatoid arthritis. The company also raised $9.5 million in a Series A funding recently.
